A deeper understanding of innate/acquired resistance to the different TKIs already available for clinical use and the development of new effective treatment strategies to overcome it, represent a current area of intense investigation and has been extensively debated within different papers published in the series.
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas
Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
The series “Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Drs. Silvia Novello and Francesco Passiglia served as the unpaid Guest Editors for the series.